Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q3 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $3.12 million versus the consensus estimate of $963.67 thousand.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.